Loading clinical trials...
Loading clinical trials...
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis
Conditions
Interventions
REGN3500
REGN3500-Matching Placebo
Locations
89
United States
Regeneron Study Site
Birmingham, Alabama, United States
Regeneron Study Site
Phoenix, Arizona, United States
Regeneron Study Site
Scottsdale, Arizona, United States
Regeneron Study Site
Tucson, Arizona, United States
Regeneron Study Site
Little Rock, Arkansas, United States
Regeneron Study Site
Fountain Valley, California, United States
Start Date
November 13, 2018
Primary Completion Date
March 13, 2020
Completion Date
July 24, 2020
Last Updated
June 10, 2022
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions